Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

Earlier this year, Amgen cleared another regulatory hurdle when its KRAS blocker Lumakras won the FDA’s blessing for use in colorectal cancer. The label expansion, which came in January, was a ...

MTA-HUN-REN TTK Lendület (Momentum) Glycan Biomarker Research Group, HUN-REN Research Centre for Natural Sciences, Magyar Tudósok Körútja 2, Budapest H-1117, Hungary National Korányi Institute of ...